Guangzhou LBP Medicine Science & Technology Co 688393.SS · CNY
Health Care · Shanghai · 🇨🇳 China
17.40
-1.42%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Guangzhou LBP Medicine Science & Technology Co
Its shares trade on Shanghai under the ticker 688393.SS. It has been listed since 20 August 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥347.3m and a net loss of CN¥45.0m. At that date it held total assets of CN¥1.29bn and shareholders' equity of CN¥1.18bn.
Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research and development, production, and sale of in vitro diagnostic reagents and instruments. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2020-08-20. The Company’s main products are pathological diagnostic reagents and instruments, covering three major technology platforms for cytological diagnosis, molecular diagnosis and immunodiagnosis, including LBP series, IHC series, PCR series and FISH series, such as integrated slide and dyeing machine, liquid-based cell and microorganism processing, preservation reagents, automatic nucleic acid molecular hybridization instrument, automatic slide processing system and immunochromogenic reagents, etc. Its products are mainly used in pathological diagnosis of tumors. The firm operates its businesses within the domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 20 Aug 2020
- Employees
- 872
- Website
- gzlbp.com ↗
Leadership
Pay as last reported
- Mr. Xiangting CaiChairman of the Board, General Manager, since 2014CN¥961,600
- Mr. Quanneng HouChief Financial OfficerCN¥503,700
- Mr. Shaoyu ChenDeputy General Manager, Director of Research Institute, Director, since 2020CN¥956,300
- Mr. Zhefeng DengDeputy General Manager, Director, since 2020CN¥516,900
- Mr. Zongsheng LiangDeputy General Manager, Director, since 2014CN¥939,300
- Mr. Wuke ChenChief Equipment R&D Officer, since 2014CN¥967,800
- Ms. Xinglun CaiSecretary of the Board, Director, since 2021CN¥639,700
- Mr. Haijiao WangDirector
- Mr. Wenping PengIndependent Director
- Mr. Hongri WuIndependent DirectorCN¥80,000
- Mr. Xiang WuIndependent DirectorCN¥80,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Guangzhou LBP Medicine Science & Technology Co Ltd employs 872 full-time employees in Guangzhou, China.
- The company's main products include LBP series and IHC series for pathological diagnosis.
- Guangzhou LBP's technology platforms cover cytological, molecular, and immunodiagnosis.
Weaknesses
- Guangzhou LBP's IPO was on 20 August 2020, which may indicate limited market history.
- The company's business is focused on a single sector, Health Care, increasing vulnerability.
- Guangzhou LBP's products are primarily for tumor diagnosis, limiting market diversity.
Opportunities
- Guangzhou LBP can expand its market reach in the growing Health Care industry.
- The company can leverage its three technology platforms for new product development.
- Guangzhou LBP's overseas market presence offers potential for international growth.
Threats
- Guangzhou LBP faces competition from other Health Care companies in China.
- The company's reliance on tumor diagnosis may be affected by changes in medical trends.
- Guangzhou LBP's IPO date of 2020 may impact investor confidence.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.